Automatic Data Processing Inc vs Mesoblast Limited — how do they compare? Automatic Data Processing Inc trades at $269.5 (market cap $108.72B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Automatic Data Processing Inc is far larger — about 50.3× Mesoblast Limited's market cap, and Automatic Data Processing Inc pays a 2.48% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ADP | MESO | |
|---|---|---|
Market Cap | $108.72B | $2.16B |
Sector | Industrials | Technology |
52-Week High | $309.03 | $20.96 |
52-Week Low | $188.79 | $12.88 |
Enterprise Value | $109.76B | $2.17B |
Dividend Yield | 2.48% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Latest headlines on both assets
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →